D-Mannose for UTIs: What the Trials Found

The tub sits beside the toothpaste in a surprising number of bathrooms: white powder, a scoop, a label promising bladder support. Short videos have pushed it back into feeds this year, with creators calling it the natural answer to recurrent bladder infections and racking up tens of millions of views. Searches for d-mannose have climbed in step.

What the clips rarely mention is that the question was put to a proper test. In April 2024, researchers in the United Kingdom published a double-blind, placebo-controlled trial of nearly 600 women with recurrent infections, and the supplement did not beat a look-alike placebo powder. As of June 2025, that study remains the most rigorous evidence available, and it changed how many clinicians talk about the product.

So the honest story is more interesting than either the hype or the dismissal. Here is what the trials found, why they disagree, and how to think about a tub of sugar when your bladder keeps betraying you.

What changed recently: the d-mannose trial that reset the conversation

For a decade, the case for d-mannose rested largely on one 2014 study from Croatia. It followed 308 women with a history of recurrent cystitis for six months and reported that those taking the sugar had far fewer repeat infections than women given nothing, and roughly as few as those on a preventive antibiotic. It was published in a respected urology journal, and it traveled fast.

The 2024 study, known as the MERIT trial and published in JAMA Internal Medicine on 8 April 2024, was designed to do what the Croatian study had not: compare d-mannose against a placebo nobody could tell apart. Investigators recruited 598 women from 99 primary care practices across England. Each had experienced at least two infections in the previous six months or three in the previous year. Half took daily d-mannose powder; half took an identical-looking powder made of fructose. Neither the women nor their doctors knew who had which.

After six months, 51.0 percent of the d-mannose group had at least one clinically suspected UTI that required a medical consultation, compared with 55.7 percent of the placebo group. The gap was within the margin of chance. Antibiotic prescriptions, hospital admissions and the number of days women felt moderately unwell did not differ either. The authors concluded that d-mannose should not be recommended to prevent future episodes in this population.

Two further things happened in the background. A Cochrane systematic review published in August 2022 had already pooled seven studies with 719 participants and judged the certainty of evidence to be very low, meaning the true effect could be anywhere from helpful to nil. And the supplement market kept growing regardless, which is why the gap between the shelf and the science is now wide enough to deserve a careful explainer.

What is d-mannose, and where does it come from?

D-mannose is a monosaccharide, which means a single sugar unit that cannot be broken down into anything simpler. It is a close chemical cousin of glucose: the same six carbons and the same formula, with one hydroxyl group pointing in a different direction. That small twist changes how the body handles it.

Small amounts occur naturally in cranberries, apples, oranges, peaches, blueberries and some seaweeds, which is partly why the cranberry connection keeps coming up. Your body also makes mannose on its own, because it is a building block for glycoproteins, the sugar-decorated proteins that sit on the surface of nearly every cell.

The supplement form is manufactured, usually from corn or birch, and sold as loose powder, capsules or tablets. In the United States it is regulated as a dietary supplement, not a drug. In practice that means the Food and Drug Administration does not review it for effectiveness before sale, manufacturers may not legally claim it treats or prevents any disease, and product purity varies from brand to brand. In the United Kingdom and much of Europe it sits in a similar category, available over the counter as a food supplement or, in some countries, a medical device.

Here is the pharmacological quirk that made researchers interested in the first place. When swallowed, d-mannose is absorbed in the upper gut but the body metabolizes very little of it. Most of the absorbed sugar passes through the kidneys and leaves in the urine within a few hours, chemically unchanged. A molecule that reaches the bladder intact, in a form bacteria recognize, is an unusually convenient candidate for a bladder-focused intervention. Whether convenience translates into fewer infections is a different question, and the next sections take it in turn.

How is d-mannose supposed to work in the bladder?

Picture the bladder lining as a wall studded with tiny sugar handles. Uropathogenic Escherichia coli, the bacterium behind roughly three quarters or more of uncomplicated bladder infections, grows hair-like filaments called type 1 fimbriae. At the tip of each sits a protein called FimH, which is a lectin, meaning a protein that grips specific sugars. FimH grips mannose. The bladder’s umbrella cells display a mannose-rich protein called uroplakin, so the bacteria latch on, resist being flushed out, and begin to invade and multiply.

The theory of d-mannose is competitive distraction. Flood the urine with free mannose and the FimH tips will bind to the loose sugar instead of the wall. Bacteria that cannot anchor get washed out with the next void. Laboratory work supports each step: mannose blocks E. coli adhesion to bladder cells in a dish, and in mice, mannose-like compounds reduce bacterial counts in the bladder. Preclinical evidence for the mechanism is genuinely strong.

The gaps appear when you move from mouse to human. The concentration of mannose that reaches urine after an oral dose may be lower and briefer than what worked in the laboratory. Not every E. coli strain depends on type 1 fimbriae at every stage of infection, and some bacteria tuck themselves inside bladder cells, forming reservoirs that free sugar in the urine cannot reach. Other urinary pathogens, including Klebsiella, Proteus, Enterococcus and Staphylococcus saprophyticus, do not rely on FimH in the same way, so the mechanism offers them no obstacle at all.

None of this disproves the idea. It explains why a plausible mechanism and a convincing clinical trial are two separate hurdles, and why only the second one tells you whether the powder on the shelf will keep you out of the clinic.

What are the benefits of taking d-mannose, according to the research?

Strip away the marketing and the candidate benefits reduce to three claims: fewer recurrent infections in women, faster relief during an active infection, and less antibiotic use overall. Each has a different weight of evidence behind it.

Prevention in women with recurrent UTIs is the best-studied claim. The 2014 Croatian trial reported recurrence in about 15 percent of women on d-mannose versus roughly 61 percent of women on no prophylaxis, a striking difference. A small Italian crossover study the same year, with around 60 women, and a 2016 Italian study also reported benefit. Then came the 2024 placebo-controlled trial of 598 women, which found no significant difference. When the largest, blinded study points one way and several smaller, unblinded studies point the other, the standard scientific reading is that the earlier results were probably inflated by bias and the real effect, if any, is small.

Treatment of an acute infection is the weakest claim. No adequately sized randomized trial has shown that d-mannose clears a symptomatic bladder infection. Some small studies gave it alongside antibiotics and measured symptom scores, but those designs cannot separate the sugar’s contribution from the antibiotic’s. Mainstream sources agree it is not a treatment for an established infection.

Reduced antibiotic use is the most appealing public health hope, because every avoided course slows the spread of resistance. The 2024 trial measured this directly: women on d-mannose received antibiotics about as often as women on placebo. That is the clearest current answer.

What remains is a tolerable supplement with a sound rationale, modest side effects and no proven clinical benefit in the one group studied carefully. That is not nothing, but it is less than the label implies.

What the evidence actually says, graded by strength

Evidence comes in tiers. At the top sit large randomized trials in which participants are blinded to what they receive. Below them are open-label randomized trials, then observational studies that watch what people choose to do, then laboratory and animal work, and finally expert opinion. Here is how d-mannose stacks up.

Laboratory and animal data: strong. The FimH binding mechanism is well characterized and reproducible. This tells us the idea is plausible, not that it works in people.

Open-label randomized trials: moderate volume, high risk of bias. The 2014 trial of 308 women compared d-mannose with an antibiotic and with no treatment, but nobody was blinded and there was no placebo. Women who know they are taking something, and doctors who know it too, record and interpret symptoms differently. The Cochrane reviewers downgraded this body of work to very low certainty for exactly these reasons.

Blinded, placebo-controlled randomized trial: one, large, negative. The 2024 trial is the only study of its kind at scale. It was preregistered, powered to detect a clinically meaningful difference, and run in ordinary primary care rather than a specialist clinic, which makes its findings more relevant to most readers. It found none.

Observational data: scarce and uninformative. Surveys of supplement users cannot tell you whether the product helped or whether the people who buy it differ in other ways.

Expert opinion and guidelines: cautious. Major urology guidance on recurrent UTI either does not recommend d-mannose or lists it as an option with weak evidence that patients may choose to try. After 2024, several guideline groups flagged the new trial for review.

The overall grade, in plain language: a promising mechanism that has not survived its first rigorous clinical test. Future trials in different populations could change that, and honest science leaves the door open. For now, the burden of proof has not been met.

Why did the 2014 trial and the 2024 trial disagree?

Two randomized trials, two opposite answers. Readers often assume one must be fraudulent or incompetent. Usually the explanation is more mundane and more instructive.

The first difference is blinding. In the 2014 study, women knew whether they had been given d-mannose, an antibiotic or nothing. The comparison that produced the dramatic headline, 15 percent versus 61 percent, was between women taking something and women taking nothing at all. Expectation shapes symptom reporting, decisions to seek care and even the threshold at which a clinician orders a urine test. The 2024 study removed that influence with a matching placebo, and the difference largely disappeared.

The second is the comparator. A placebo of fructose powder is not inert in the psychological sense: both groups in 2024 performed a daily ritual that felt like prevention. If part of the earlier benefit was ritual, placebo control would absorb it.

The third is setting and definition. The 2014 participants were recruited from a hospital clinic in one country and diagnosed by positive urine cultures. The 2024 participants came from 99 general practices, and the outcome counted clinically suspected infections that led to a consultation, which is closer to what a patient actually experiences. Broader, messier populations tend to show smaller effects.

The fourth is size and statistics. Nearly 600 participants gave the 2024 trial enough power to detect a five-point difference in recurrence as real if it existed. The observed gap was under five points and the confidence interval crossed zero.

Is it possible d-mannose helps a specific subgroup, perhaps women whose infections are all culture-proven E. coli with type 1 fimbriae? Possible, and untested. But the trial designed to find a general benefit in the people most likely to buy the product did not find one, and that should weigh heavily.

Is d-mannose the same as cranberry? D-mannose vs cranberry explained

They are related, which is why the confusion is forgivable, but they are not the same thing and the evidence for each has moved in different directions.

Cranberries contain small amounts of mannose, yet the component credited with their antibacterial reputation is a different class of molecule entirely: A-type proanthocyanidins, plant compounds that also appear to interfere with E. coli adhesion, though through a different fimbrial system. Cranberry products therefore deliver trace mannose plus proanthocyanidins plus a great deal of sugar or, in capsule form, a concentrated extract whose proanthocyanidin content varies widely between brands.

The research record is also different. A 2023 Cochrane update on cranberry products pooled 50 studies and more than 8,800 participants and concluded that cranberry probably reduces the risk of symptomatic, culture-verified UTIs in women with recurrent infections, in children, and in people undergoing certain procedures. Benefit was less clear in older adults in care homes and in people using catheters. That is a moderate-certainty positive signal across many trials, something d-mannose does not currently have.

The caveats still matter. Cranberry juice is a poor vehicle because of its sugar load, and the effect size, where it exists, is modest. Several well-run individual trials have been negative. Cranberry is also a prevention strategy, not a treatment; nobody should sip juice instead of seeking care for a symptomatic infection.

Combination products that pair d-mannose with cranberry extract are common. No large trial has tested the combination against placebo, so claims of synergy are untested rather than disproven. If a reader wants a plant-based preventive with some trial support behind it, the honest answer as of 2025 is that cranberry extract has more than d-mannose does, and the comparison in the next section lays the alternatives side by side.

D-mannose compared with other ways to prevent recurrent UTIs

Recurrent UTI is usually defined as two confirmed infections in six months or three in a year. For women who meet that threshold, several strategies have been tested in randomized trials. The table summarizes the state of play; it is a map of evidence quality, not a menu, and the choice belongs in a conversation with your clinician.

Strategy	Type of evidence	What it showed	Current standing
D-mannose	One large blinded RCT (2024), several small open-label RCTs	No significant benefit versus placebo; earlier unblinded trials positive	Not recommended in major guidance; low-risk option some patients still choose
Cranberry extract	50 RCTs pooled (Cochrane 2023)	Probable modest reduction in recurrences in women	Conditional recommendation in some guidelines
Increased daily fluid intake	One RCT in women drinking little water at baseline	About half as many recurrences over 12 months	Widely advised; low risk
Vaginal estrogen (after menopause)	Multiple RCTs	Fewer recurrences; restores protective vaginal flora	Recommended for postmenopausal women; prescription required
Methenamine hippurate	Large pragmatic RCT (2022)	Non-inferior to daily preventive antibiotics	Increasingly used as an antibiotic-sparing option; prescription
Preventive antibiotics	Many RCTs over decades	Strong reduction while taken; resistance and side effects are trade-offs	Reserved for frequent, documented recurrences

Two patterns stand out. First, the strongest evidence belongs to prescription strategies, which is why repeated infections deserve a medical review rather than a self-managed supplement routine. Second, the lowest-risk measures, more fluids and sensible hygiene, carry real if modest support and cost nothing. D-mannose sits in an awkward middle: safer than antibiotics, less proven than anything else on the list.

Can you take d-mannose with antibiotics for a UTI?

This is one of the most common questions, usually asked by someone mid-infection with a prescription in one hand and a supplement tub in the other. The short answer: there is no known chemical interaction between d-mannose and the antibiotics typically prescribed for bladder infections, and small studies have given the two together without reported harm. The longer answer is that adding it is unlikely to change your outcome.

Think about what each is doing. The antibiotic kills or disables bacteria already established in the bladder wall and urine. D-mannose, at best, discourages new bacteria from attaching. During an active infection, attachment has already happened, and some bacteria have moved inside bladder cells where urine sugar cannot follow. A couple of small open-label studies reported slightly faster symptom improvement when d-mannose accompanied an antibiotic, but without blinding or placebo those findings are too weak to act on.

Three practical cautions follow from the evidence rather than from theory.

• Never use d-mannose instead of a prescribed antibiotic, or as a reason to stop one early. Incompletely treated bladder infections can ascend to the kidneys.
• Tell your prescriber what supplements you take. Loose stools are a common d-mannose side effect, and several UTI antibiotics also upset the gut; stacking them can muddy the picture if diarrhea develops.
• Do not let a supplement delay a urine test. A sample taken before antibiotics start identifies the organism and its sensitivities, which matters most for people with repeat infections.

Whether to continue or start d-mannose during or after a course is a decision for the clinician treating you, who can weigh your culture results, your recurrence history and any other conditions. The supplement is not dangerous in this context; it is simply not doing the work people hope it is doing.

D-mannose side effects and who should be cautious

Safety is the one area where the evidence and the marketing broadly agree. Across the randomized trials, d-mannose was well tolerated, and in the 2024 study adverse events were similar between the supplement and placebo groups. That said, mild effects are real and a few groups deserve specific caution.

The most frequently reported side effects are gastrointestinal: loose stools, bloating and mild abdominal discomfort. The explanation is simple physics. Unabsorbed sugar draws water into the bowel, which is the same reason sugar alcohols in chewing gum can have a laxative effect. In the 2014 trial, around 8 percent of women on d-mannose reported diarrhea, and it was generally mild.

People with diabetes should raise it with their care team before starting. D-mannose is a sugar, and although the body handles it differently from glucose and most trial data suggest minimal effect on blood glucose, long-term use has not been studied in people with impaired glucose control. Anyone monitoring their numbers closely should know what they are adding.

Pregnancy and breastfeeding fall into an evidence gap. The 2024 trial excluded pregnant women, as did most earlier studies. No harm signal exists, but no reassurance exists either, and urinary infections in pregnancy carry higher stakes, which the fertility section covers below.

Children have been included in only a small number of studies. Kidney disease is another reason for caution, because the kidneys are the exit route for the sugar and reduced function changes that calculation in ways no trial has examined.

Finally, remember that supplement quality is not independently verified before sale. Choosing products that carry third-party testing seals reduces, but does not eliminate, the risk of contamination or mislabeled content. If anything unexpected happens after starting a supplement, stop and discuss it with a clinician rather than pushing through.

What can I take daily to prevent UTI? What the guidelines actually back

The impulse behind this question is sound: when infections keep coming, you want something proactive. The evidence-based answer is less about a single product and more about matching the strategy to the reason your infections recur.

Start with the basics that have trial support. A randomized study in women who habitually drank little water found that increasing daily fluid intake roughly halved recurrences over a year, from about three episodes to under two. More urine means more frequent flushing of the bladder. Emptying the bladder soon after sexual intercourse is widely recommended; the trial evidence is weaker, but the rationale is reasonable and the downside is nil. Avoiding spermicides and spermicide-coated diaphragms matters more than most people realize, because observational studies consistently link them with higher infection risk through changes in vaginal bacteria.

For postmenopausal women, the single most effective daily measure in randomized trials is prescription vaginal estrogen, applied locally rather than taken by mouth. Falling estrogen thins the urethral lining and lets protective Lactobacillus species give way to gut bacteria; restoring estrogen locally reverses that shift and has repeatedly reduced recurrences in trials.

Among over-the-counter options, cranberry extract has the best, if modest, trial record, as discussed above. D-mannose is the one people ask about most and the one with the weakest current support.

When infections are frequent and culture-confirmed, prescription prevention enters the discussion. Methenamine hippurate, which releases formaldehyde in acidic urine, performed as well as daily antibiotics in a large 2022 trial, with less resistance pressure. Continuous or post-intercourse preventive antibiotics remain the most powerful tool, held in reserve because of side effects and resistance.

Each of those prescription options involves decisions about duration, monitoring and suitability that belong to the clinician who knows your history. The daily habit worth adopting first is the appointment to talk it through.

Common myths about d-mannose, corrected

Viral health content thrives on confident one-liners. Here are the ones circulating most widely about d-mannose, and what the evidence says about each.

Myth: it works as well as antibiotics. This traces to the 2014 trial, where recurrence rates on d-mannose and on a preventive antibiotic looked similar. But that study had no placebo group and no blinding, and the 2024 placebo-controlled trial found no benefit at all. Equivalence to an antibiotic has never been shown in a rigorous design.

Myth: it can clear an infection in 24 hours. No trial supports treating an active infection with d-mannose alone. Symptoms of mild cystitis sometimes settle on their own, which fuels anecdotes, but an untreated infection can also climb to the kidneys. Testimonials are not evidence.

Myth: it is just concentrated cranberry. Cranberry’s proposed active compounds are proanthocyanidins, not mannose. The two have separate mechanisms and separate, and currently unequal, research records.

Myth: because it is natural, more is better. Higher intake mainly means more unabsorbed sugar in the bowel and more digestive upset. There is no evidence of a dose-response benefit in humans.

Myth: it is safe for everyone. It is well tolerated in the healthy women who have been studied. People with diabetes, kidney disease, children and anyone pregnant or breastfeeding were largely excluded from trials, so safety there is assumed, not demonstrated.

Myth: the 2024 trial was rigged by drug companies. It was publicly funded by the United Kingdom’s National Institute for Health and Care Research and run through academic primary care networks. Its design was published in advance.

Myth: a negative trial proves it never helps anyone. A single trial, however good, estimates an average effect in one population. Subgroups and other settings remain open questions. Humility cuts both ways: no proof of benefit, no proof of futility in every circumstance.

Fertility, pregnancy and menopause: where d-mannose does and does not fit

Urinary infections cluster around three reproductive moments, and each raises a different question about supplements.

The first is sexually active early adulthood, when the mechanical act of intercourse carries gut bacteria toward the urethra. Infections in this phase are usually uncomplicated, and the prevention conversation revolves around fluids, voiding after sex, contraceptive choice and, for frequent recurrences, post-intercourse preventive antibiotics prescribed by a clinician. D-mannose is often tried here because it feels gentler than antibiotics. The 2024 trial population included many such women, and it found no benefit, so the honest advice is that it is a low-risk experiment with low odds of paying off. There is no evidence that d-mannose affects fertility, ovulation or contraception in either direction.

The second is pregnancy, and here the ground shifts. Hormonal changes slow urine flow and relax the ureters, so bacteria that would stay in the bladder can reach the kidneys more easily. Pregnant women are routinely screened for bacteria in the urine even without symptoms, because treating it reduces the risk of kidney infection and preterm birth. Supplements have no role in that pathway. D-mannose has not been studied in pregnancy, and any urinary symptom during pregnancy warrants prompt medical assessment rather than a self-managed trial of powder.

The third is perimenopause and beyond, when recurrent UTIs often appear for the first time in women who never had them. The driver is falling estrogen, which changes the vaginal and urethral environment. This is the one stage where a highly effective, trial-backed, non-antibiotic prevention exists in the form of locally applied vaginal estrogen, available by prescription. Women who reach for d-mannose at this age may be treating the wrong problem with the wrong tool, which is a strong reason to see a clinician instead of a supplement aisle.

When to see a doctor about a UTI, with or without d-mannose

A supplement should never stand between you and timely care. Bladder infections are common and usually straightforward, but some presentations need same-day attention and a few are emergencies. Use this as a guide, not a checklist for self-diagnosis.

Arrange a routine appointment if you have the classic signs of cystitis: burning when passing urine, needing to go urgently or often, pressure low in the pelvis, or urine that looks cloudy or smells unusual. A simple test and, where appropriate, a short antibiotic course can settle most episodes, and a culture is especially useful if infections recur.

Seek care the same day if symptoms do not begin to improve within two days of starting treatment, if they return within a few weeks, if you notice visible blood in the urine, or if you are pregnant, male, a child, over 65, or living with diabetes, a weakened immune system, kidney disease or a urinary catheter. In these groups, what looks like a simple infection is more likely to be complicated.

Treat the following as red flags that need urgent assessment, in an emergency department if necessary:

• Fever with chills or shaking, which can signal infection spreading to the kidneys
• Pain in the back or side, just below the ribs
• Nausea or vomiting that prevents you keeping fluids or medication down
• Confusion or sudden drowsiness, particularly in an older adult
• Feeling very unwell, breathless, or having a racing heart, which can indicate sepsis

And see a doctor about recurrence itself. Two confirmed infections in six months or three in a year is a pattern worth investigating, because it may point to a treatable cause. Every decision about preventive medicines, including whether a supplement has any place alongside them, should be made with the clinician who knows your history and your culture results.

Frequently asked questions

What are the benefits of taking D-mannose?

The only benefit with meaningful trial support is a possible reduction in recurrent bladder infections in women, and the best study to date did not confirm it. Earlier open-label trials reported fewer recurrences, but the 2024 placebo-controlled trial found no significant difference. D-mannose does not treat an active infection and did not reduce antibiotic use in that trial. It is generally well tolerated, which is the main thing in its favor.

What can I take daily to prevent UTI?

The measures with the best evidence are drinking more fluids, avoiding spermicides, and, after menopause, prescription vaginal estrogen. Cranberry extract has modest trial support. For frequent, confirmed recurrences, clinicians may consider methenamine hippurate or preventive antibiotics, which require a prescription and monitoring. D-mannose is an option many people try but currently has the weakest evidence of the group.

Is D-mannose the same as cranberry?

No. Cranberries contain trace amounts of mannose, but their proposed protective compounds are proanthocyanidins, which act on a different bacterial attachment system. The research records also differ: a 2023 review of 50 trials found cranberry probably reduces recurrences modestly, while the largest d-mannose trial found no benefit. Combination products exist, but their added value has not been tested against placebo.

Can you take D-mannose with antibiotics for UTI?

There is no known interaction, and small studies have combined them without reported harm, but the supplement is unlikely to improve your outcome during an active infection. Never use it instead of a prescribed antibiotic or as a reason to stop early. Tell your prescriber about any supplements, since both can cause loose stools. Whether to continue d-mannose afterward is a decision for your treating clinician.

Does d-mannose work for an active UTI?

No adequately designed trial shows that d-mannose clears a symptomatic infection on its own. Its proposed mechanism blocks bacteria from attaching, which is too late once infection is established and some bacteria have moved inside bladder cells. Mild cystitis occasionally settles without treatment, fueling anecdotes, but an untreated infection can spread to the kidneys. Symptoms warrant a medical assessment, not a supplement trial.

What are the d-mannose side effects?

The most common are loose stools, bloating and mild abdominal discomfort, because unabsorbed sugar draws water into the bowel. In one trial about 8 percent of women reported diarrhea, generally mild. Serious adverse effects have not been reported in studies, and in the 2024 trial side effects matched placebo. Safety has not been established in pregnancy, kidney disease or children, because those groups were largely excluded.

Is d-mannose safe for people with diabetes?

It is a sugar, so the question is reasonable. The body metabolizes very little d-mannose and most trial data suggest minimal effect on blood glucose, but long-term use in people with diabetes has not been studied. Anyone managing blood sugar should discuss it with their care team before starting, and be aware that diabetes itself raises UTI risk and makes prompt medical assessment of symptoms more important.

Can men take d-mannose for UTIs?

There is no trial evidence in men. The randomized studies, including the large 2024 trial, enrolled women only. UTIs in men are less common and more often signal an underlying problem such as prostate enlargement, so they are usually treated as complicated infections that need medical evaluation and a urine culture. A supplement is not an appropriate first response to urinary symptoms in a man.

How long does d-mannose take to work?

Absorbed d-mannose appears in urine within a few hours and is cleared within a day, so any effect would be short-lived and depend on daily use. The prevention trials assessed outcomes over six months. Because the best-designed trial found no benefit over that period, there is no evidence-based timeline for when it should start working. Persisting or worsening symptoms need a clinician, not more time.

Is d-mannose safe in pregnancy?

Unknown, because pregnant women were excluded from the trials. No harm signal exists, but neither does reassurance. More importantly, urinary infections in pregnancy carry higher risks of kidney infection and preterm birth, which is why pregnant women are screened for bacteria in the urine even without symptoms. Any urinary symptom during pregnancy should prompt a same-day medical assessment rather than self-management with a supplement.

References

• NHS: Urinary tract infections (UTIs)
• MedlinePlus: Urinary Tract Infections

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.